Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)
China
· Delayed Price · Currency is CNY 16.13
+0.07 (0.44%)
Apr 30, 2026, 11:29 AM CST
Cabio Biotech (Wuhan) Revenue
Cabio Biotech (Wuhan) had revenue of 11.01M CNY in the quarter ending March 31, 2026, a decrease of -92.94%. This brings the company's revenue in the last twelve months to 418.18M, down -29.66% year-over-year. In the year 2025, Cabio Biotech (Wuhan) had annual revenue of 563.14M with 1.36% growth.
Revenue (ttm)
418.18M
Revenue Growth
-29.66%
P/S Ratio
6.41
Revenue / Employee
740.15K
Employees
574
Market Cap
2.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 563.14M | 7.54M | 1.36% |
| Dec 31, 2024 | 555.59M | 111.79M | 25.19% |
| Dec 31, 2023 | 443.80M | 10.38M | 2.39% |
| Dec 31, 2022 | 433.42M | 82.32M | 23.44% |
| Dec 31, 2021 | 351.11M | 27.65M | 8.55% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shandong Sito Bio-technology | 954.76M |
| Suzhou Fushilai Pharmaceutical | 412.51M |
| Shanghai Universal Biotech | 1.07B |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |
| Hubei Goto Biopharm | 626.28M |
| Shanghai Hile Bio-Technology | 246.35M |
| Zhejiang East Asia Pharmaceutical | 940.19M |
| Jiangsu Sihuan Bioengineering | 344.38M |